NCCN: Updated NCCN Guidelines Recommend HEPZATO KIT for Hepatic-Dominant Uveal Melanoma
The NCCN Guidelines for metastatic uveal melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease.
Read full article »
NCCN is a Pennsylvania-based non-profit alliance of cancer centers that work to provide patient care, research, and education for individuals.
Read more